Anath Shalev MD
Diabetes, Lipid Metabolism
Professor, Medicine, University of Alabama School of Medicine
Join to View Full Profile
1825 Univ Ave Shelby Bldg# 1206Birmingham, AL 35294
Phone+1 205-996-4777
Dr. Shalev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1998 - 2001
University of Basel Faculty of MedicineClass of 1993
Certifications & Licensure
AL State Medical License 2011 - 2025
IA State Medical License 2000 - 2022
WI State Medical License 2002 - 2021
Publications & Presentations
PubMed
- Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity.SeongHo Jo, Gu Jing, Junqin Chen, Guanlan Xu, Anath Shalev
Diabetes, Obesity & Metabolism. 2025-04-01 - Data-driven Cluster Analysis Reveals Increased Risk for Severe Insulin-deficient Diabetes in Black/African Americans.Brian Lu, Peng Li, Andrew B Crouse, Tiffany Grimes, Matthew Might
The Journal of Clinical Endocrinology and Metabolism. 2025-01-21 - 1 citationsA novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging.Gu Jing, SeongHo Jo, Anath Shalev
Frontiers in Endocrinology. 2024-01-01
Lectures
- miR-200 Family Members Are Induced by TXNIP and Increase ß-Cell ApoptosisBirmingham, AL - 6/14/2014
- Thioredoxin-Interacting Protein (TXNIP) Regulates Beta-Cell Function Through miRNAsBirmingham, AL - 6/16/2014
- Differential Cytokine Effects on ß-Cell TXNIP ExpressionBirmingham, AL - 6/15/2014
- Join now to see all
Authored Content
- Presenter Profile: ADA Symposium—Major Advances and Discoveries in Diabetes—The Year in ReviewJune 2023
Press Mentions
Study Explores Whether Osteoporosis Drug Denosumab Regenerate Beta Cells?March 30th, 2025- TIXiMED Inc. Announces Successful Dosing of First Cohort in the Phase 1 Clinical Trial of TIX100, Its Investigational Disease-Modifying Treatment for Type 1 DiabetesMarch 7th, 2025
- Black/African American Individuals Have an Increased Risk for Severe Insulin-Deficient DiabetesSeptember 4th, 2024
- Join now to see all
Grant Support
- TARGETING MASH WITH NOVEL SMALL MOLECULE TXNIP INHIBITORUNIVERSITY OF ALABAMA AT BIRMINGHAM2024–2029
- Txnip Regulation Of Endogenous Beta Cell MassNational Institute Of Diabetes And Digestive And Kidney Diseases2011–2012
- Txnip Regulation Of Endogenous Beta Cell MassNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2010
- Txnip: A Novel Approach To Prevent Diabetic Cardiomyopathy And Heart FailureNational Heart, Lung, And Blood Institute2007–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
